Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
AVNS

AVNS - Avanos Medical Inc Stock Price, Fair Value and News

19.60USD-0.58 (-2.87%)Market Closed

Market Summary

AVNS
USD19.60-0.58
Market Closed
-2.87%

AVNS Alerts

  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

AVNS Stock Price

View Fullscreen

AVNS RSI Chart

AVNS Valuation

Market Cap

899.7M

Price/Earnings (Trailing)

-14.46

Price/Sales (Trailing)

1.32

EV/EBITDA

15.81

Price/Free Cashflow

28.84

AVNS Price/Sales (Trailing)

AVNS Profitability

EBT Margin

0.40%

Return on Equity

-5.07%

Return on Assets

-3.74%

Free Cashflow Yield

3.47%

AVNS Fundamentals

AVNS Revenue

Revenue (TTM)

680.1M

Rev. Growth (Yr)

4.27%

Rev. Growth (Qtr)

-4.15%

AVNS Earnings

Earnings (TTM)

-62.2M

Earnings Growth (Yr)

-80%

Earnings Growth (Qtr)

-108.57%

Breaking Down AVNS Revenue

Last 7 days

-0.7%

Last 30 days

1.5%

Last 90 days

6.3%

Trailing 12 Months

-22.1%

How does AVNS drawdown profile look like?

AVNS Financial Health

Current Ratio

2.28

Debt/Equity

0.14

Debt/Cashflow

0.19

AVNS Investor Care

Buy Backs (1Y)

1.63%

Diluted EPS (TTM)

-1.33

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024680.1M000
2023665.0M663.5M662.5M673.3M
2022603.7M588.2M576.4M703.1M
2021715.1M737.8M736.2M587.0M
2020713.8M705.3M719.6M714.8M
2019660.1M671.4M677.7M697.6M
2018622.3M634.1M648.7M652.3M
2017577.5M588.9M600.3M611.6M
2016523.3M537.6M551.9M566.2M
20151.7B1.6B1.6B509.0M
20141.7B1.7B1.7B1.7B
2013001.7B1.7B
20120001.7B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Avanos Medical Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 18, 2024
holbrook kerr
acquired
-
-
2,531
svp, chief commercial officer
Mar 18, 2024
holbrook kerr
sold (taxes)
-68,647
19.09
-3,596
svp, chief commercial officer
Mar 18, 2024
woody joseph fralin
acquired
-
-
15,821
chief executive officer
Mar 18, 2024
woody joseph fralin
sold (taxes)
-644,574
19.09
-33,765
chief executive officer
Mar 18, 2024
greiner michael
acquired
-
-
4,219
svp - chief financial officer
Mar 18, 2024
greiner michael
sold (taxes)
-171,905
19.09
-9,005
svp - chief financial officer
Mar 14, 2024
greiner michael
sold
-152,980
19.1225
-8,000
svp - chief financial officer
Mar 11, 2024
shimer julie ann
bought
9,925
19.85
500
-
Mar 06, 2024
varshney sudhakar
sold (taxes)
-26,486
19.00
-1,394
svp, global supply chain
Mar 06, 2024
hurley john joseph
acquired
35,007
19.14
1,829
principal accounting officer

1–10 of 50

Which funds bought or sold AVNS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
reduced
-36.7
-2,395
2,495
-%
Jun 06, 2024
WESTWOOD HOLDINGS GROUP INC
reduced
-1.7
-6,149,000
42,100,000
0.33%
May 30, 2024
CAMBRIDGE TRUST CO
sold off
-100
-90.00
-
-%
May 28, 2024
Boston Partners
new
-
571,120
571,120
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-39,000
308,000
-%
May 17, 2024
VIMA LLC
new
-
149
149
-%
May 16, 2024
Clear Point Advisors Inc.
unchanged
-
-63.00
498
-%
May 16, 2024
Ancora Advisors LLC
unchanged
-
-48.00
378
-%
May 16, 2024
COMERICA BANK
reduced
-8.49
-115,164
498,335
-%
May 16, 2024
Tidal Investments LLC
new
-
439,434
439,434
0.01%

1–10 of 48

Are Funds Buying or Selling AVNS?

Are funds buying AVNS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AVNS
No. of Funds

Unveiling Avanos Medical Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
rgm capital, llc
6.83%
3,171,455
SC 13G/A
Feb 13, 2024
vanguard group inc
11.67%
5,417,952
SC 13G/A
Feb 09, 2024
dimensional fund advisors lp
6.1%
2,854,235
SC 13G/A
Feb 07, 2024
paradice investment management llc
3.6%
1,653,312
SC 13G/A
Jan 22, 2024
blackrock inc.
16.1%
7,461,343
SC 13G/A
Feb 13, 2023
rgm capital, llc
5.71%
2,653,104
SC 13G/A
Feb 10, 2023
dimensional fund advisors lp
6.2%
2,891,836
SC 13G
Feb 09, 2023
vanguard group inc
11.83%
5,500,000
SC 13G/A
Feb 08, 2023
paradice investment management llc
5.0%
2,343,232
SC 13G/A
Jan 26, 2023
blackrock inc.
16.3%
7,571,048
SC 13G/A

Recent SEC filings of Avanos Medical Inc

View All Filings
Date Filed Form Type Document
May 28, 2024
SD
SD
May 20, 2024
3
Insider Trading
May 13, 2024
8-K
Current Report
May 02, 2024
10-Q
Quarterly Report
May 02, 2024
8-K
Current Report
Apr 29, 2024
8-K
Current Report
Mar 19, 2024
4
Insider Trading
Mar 19, 2024
4
Insider Trading
Mar 19, 2024
4
Insider Trading
Mar 18, 2024
ARS
ARS

Peers (Alternatives to Avanos Medical Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.0B
40.3B
-0.37% 2.47%
31.97
4.46
-2.84% -3.00%
67.0B
19.7B
-1.25% -6.96%
50.29
3.4
4.82% -17.56%
20.4B
3.9B
-2.42% -17.36%
44.2
5.22
5.72% 46.72%
17.2B
14.9B
-5.98% -23.37%
6.49
1.15
2.98% 207.68%
MID-CAP
9.7B
3.5B
-1.37% 26.59%
30.88
2.73
6.16% 35.06%
8.5B
12.4B
-9.19% -12.63%
21.86
0.68
-0.93% -18.83%
8.0B
2.6B
-0.75% -24.43%
-24.93
3.09
-6.25% -68.58%
5.5B
3.9B
-4.01% -30.77%
-58.03
1.41
0.23% 90.80%
3.4B
387.1M
-0.49% 33.89%
-215.53
8.87
30.82% 65.57%
2.0B
6.6B
-10.56% -17.38%
10.59
0.31
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
21.26% 13.50%
-2.22
0.48
7.94% -1695.32%
385.1M
169.3M
2.11% -4.54%
-5.01
2.28
7.49% -244.90%
248.7M
324.0M
0.33% -43.67%
-1.29
0.77
-3.19% -337.41%
50.6M
50.5M
8.39% -77.60%
-2.22
1
14.25% -10.06%
1.8M
3.7M
-47.47% -84.71%
-0.15
0.49
5.77% 8.23%

Avanos Medical Inc News

Latest updates
MarketBeat10 Jun 202409:36 pm
GuruFocus.com28 May 202403:19 pm
Yahoo Movies UK27 May 202409:41 pm
Yahoo Finance03 May 202407:00 am

Avanos Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In null)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-4.2%16617317116915916317217119736.00184186181185186164180190171172164
Gross Profit-0.2%95.0095.0096.0098.0091.0094.0010010210732.0090.0086.0091.0087.0096.0087.0010211095.0099.0099.00
  S&GA Expenses12.2%84.0075.0079.0093.0089.0077.0078.0083.0090.0060.0075.0077.0073.0082.0082.0077.0091.0010494.0095.00106
  R&D Expenses2.9%7.007.006.007.008.007.007.008.008.006.008.008.008.0010.008.008.009.008.0010.0010.0010.00
EBITDA Margin16.7%0.09*0.08*0.09*0.11*0.12*0.13*0.09*0.07*0.04*0.00*-0.03*-0.04*---------
Interest Expenses-6.1%3.003.005.004.004.003.003.003.001.001.001.001.001.003.004.004.004.004.004.004.004.00
Income Taxes147.6%1.00-2.106.00-0.80-1.303.00-0.903.002.003.0038.00-46.00-5.80-0.80-23.50-2.90-6.70-0.40-8.80-3.30-5.60
Earnings Before Taxes-83.1%2.009.00-2.60-5.10-9.108.0010.008.007.00-23.103.00-7.50-14.20-49.80-4.20---6.50-20.30-11.30-25.90
EBT Margin133.8%0.00*-0.01*0.00*0.02*0.04*0.05*0.00*-0.01*-0.03*-0.07*-0.09*-0.10*---------
Net Income-108.6%-0.9011.00-3.70-68.10-0.5017.0016.0013.005.0012.00-35.3039.00-8.40-49.0019.00-3.004.00-6.10-11.50-8.00-20.30
Net Income Margin0.4%-0.09*-0.09*-0.08*-0.05*0.06*0.07*0.08*-0.01*0.03*0.01*-0.07*0.00*---------
Free Cashflow-163.0%-8.0013.0029.00-2.60-6.8034.0028.0027.002.0052.0023.0015.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.8%1,6611,6921,7251,6671,7351,7871,7751,7531,7671,6041,5981,6831,6491,6731,7991,7561,7641,8001,8081,7831,834
  Current Assets-3.9%468487525507454624470437439428405444448467568517524539547573660
    Cash Equivalents-13.6%76.0088.0010782.0096.0012811710710411998.00100100112180185188205214288348
  Inventory1.5%166163157148200132194169158159158160165169184174153146145134130
  Net PPE-0.9%116117117123164119163164167168170172173175177179179185182174160
  Goodwill-0.2%79579679276382276082482582674380280380280380180080080119.0014.00784
Liabilities-5.0%433456503432436496512501510333336387396416509494507534541507554
  Current Liabilities-12.5%205235171161159191162151153139129158155166179176189213218187238
  Long Term Debt4.9%167159258203205226248249254130145165175180249248248248248248248
    LT Debt, Current9.3%9.009.006.006.006.006.006.005.00-------------
    LT Debt, Non Current------226---130-------248---
Shareholder's Equity-0.7%1,2281,2361,2221,2351,2991,2911,2641,2591,6331,2711,2671,3021,2571,2621,2901,2621,2571,2731,2671,2771,280
  Retained Earnings-0.3%-315-314-325-321-253-253-270-293-304-303-320-285-323-309-268-287-284-288-282-270-262
  Additional Paid-In Capital0.2%1,6681,6641,6601,6551,6511,6461,6421,6371,6331,6291,6261,6211,6171,6091,6041,6001,5961,5941,5921,5871,583
Shares Outstanding-0.2%46.0046.0046.0047.0047.0047.0046.0047.0047.0048.0048.0048.00---------
Float----1,192---1,279---1,748---1,403---2,076-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-163.0%-8,00012,70029,100-2,600-6,80033,70028,40027,0001,80052,10023,20015,300-3,3001,1001,1001,100-5,800-2,900-16,600-31,900-23,100
  Share Based Compensation-10.0%3,6004,0003,9003,9004,0004,0004,1004,0003,8003,0003,5003,6003,1003,2003,4003,0002,5001,7002,8001,8004,200
Cashflow From Investing-102.5%-2,00081,000-48,900-6,500-4,000-4,900-4,700-4,100-121,700-4,700-4,800-5,800-5,700-5,100-7,000-6,900-5,200-8,100-57,600-29,900-12,500
Cashflow From Financing99.4%-700-114,70046,700-4,100-22,100-21,900-10,200-16,900105,700-25,800-19,200-10,100-200-68,300-2,000300--1002,500800-1,700
  Buy Backs46.8%9,1006,2009,2002,6001,10040011,00014,70019,40010,900100500-500100300-2001001,4001,900
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AVNS Income Statement

2024-03-31
CONDENSED CONSOLIDATED INCOME STATEMENTS - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Net Sales$ 166.1$ 159.3
Cost of products sold71.367.9
Gross Profit94.891.4
Research and development7.07.5
Selling and general expenses83.688.8
Other expense, net0.21.2
Operating Income (Loss)4.0(6.1)
Interest income0.60.5
Interest expense(3.1)(3.5)
Income (Loss) Before Income Taxes1.5(9.1)
Income tax (provision) benefit(1.0)1.3
Income (Loss) from Continuing Operations0.5(7.8)
(Loss) Income from discontinued operations, net of tax(1.4)7.3
Net Loss$ (0.9)$ (0.5)
Basic Earnings (Loss) Per Share  
Continuing operations- basic (in dollars per share)$ 0.01$ (0.17)
Discontinued operations- basic (in dollars per share)(0.03)0.16
Basic Earnings (Loss) Per Share (in dollars per share)(0.02)(0.01)
Diluted Earnings (Loss) Per Share  
Continuing operations- diluted (in dollars per share)0.01(0.17)
Discontinued operations- diluted (in dollars per share)(0.03)0.16
Diluted Earnings (Loss) Per Share (in dollars per share)$ (0.02)$ (0.01)

AVNS Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current Assets  
Cash and cash equivalents$ 75.8$ 87.7
Accounts receivable, net of allowances131.3142.8
Inventories165.6163.2
Prepaid and other current assets28.628.8
Assets held for sale66.564.5
Total Current Assets467.8487.0
Property, Plant and Equipment, net116.2117.2
Operating Lease Right-of-Use Assets24.226.8
Goodwill794.9796.1
Other Intangible Assets, net232.8239.5
Deferred Tax Assets6.36.5
Other Assets19.119.3
TOTAL ASSETS1,661.31,692.4
Current Liabilities  
Current portion of long-term debt9.48.6
Current portion of operating lease liabilities11.512.8
Trade accounts payable57.056.3
Accrued expenses75.193.2
Liabilities held for sale52.263.7
Total Current Liabilities205.2234.6
Long-Term Debt167.2159.4
Operating Lease Liabilities26.628.3
Deferred Tax Liabilities23.623.8
Other Long-Term Liabilities10.810.0
Total Liabilities433.4456.1
Commitments and Contingencies
Stockholders’ Equity  
Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued0.00.0
Common stock - $0.01 par value - authorized 300,000,000 shares, 46,066,997 outstanding as of March 31, 2024 and 46,174,337 outstanding as of December 31, 20230.50.5
Additional paid-in capital1,667.71,663.6
Accumulated deficit(315.8)(314.9)
Treasury stock(95.0)(85.9)
Accumulated other comprehensive loss(29.5)(27.0)
Total Stockholders’ Equity1,227.91,236.3
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 1,661.3$ 1,692.4
AVNS
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy and OrthogenRx's knee osteoarthritis pain relief injection products. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
 CEO
 WEBSITEhttps://avanos.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES4044

Avanos Medical Inc Frequently Asked Questions


What is the ticker symbol for Avanos Medical Inc? What does AVNS stand for in stocks?

AVNS is the stock ticker symbol of Avanos Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avanos Medical Inc (AVNS)?

As of Wed Jun 12 2024, market cap of Avanos Medical Inc is 926.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVNS stock?

You can check AVNS's fair value in chart for subscribers.

What is the fair value of AVNS stock?

You can check AVNS's fair value in chart for subscribers. The fair value of Avanos Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avanos Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVNS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avanos Medical Inc a good stock to buy?

The fair value guage provides a quick view whether AVNS is over valued or under valued. Whether Avanos Medical Inc is cheap or expensive depends on the assumptions which impact Avanos Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVNS.

What is Avanos Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, AVNS's PE ratio (Price to Earnings) is -14.89 and Price to Sales (PS) ratio is 1.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVNS PE ratio will change depending on the future growth rate expectations of investors.